Creating novel treatments
for amyloid diseases
ADRx is advancing drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The ADRx team has developed ADvantage, a novel drug discovery technology platform that leverages our deep understanding of amyloid protein structure, aggregation and function. ADRx has employed its ADvantage technology to design and evolve novel compounds to address unmet medical needs in amyloid diseases. ADRx is a privately funded preclinical stage biotechnology company located in Thousand Oaks, California.